Control of feline leukaemia virus.
Feline leukaemia virus (FeLV) usually occurs in its natural species, the domestic cat. FeLV is also important to human individuals as a comparative model, as it may cause a variety of diseases, some malignant and some benign, such as immunosuppression, which bears a resemblance to AIDS (acquired immune deficiency syndrome) in man. FeLV is transmitted among cats by contagion. The main sources of infection are persistently infected carrier cats which continuously excrete virus. Dissemination of FeLV among cats may be prevented by identifying infected carrier cats and removing them from contact with non-infected cats. Removal programmes using indirect immunofluorescence antibody tests were applied successfully in The Netherlands. The proportion of FeLV-positive cats decreased from 9% in 1974 to approximately 3% in 1985 during such a programme. The results of a removal programme carried out in a catbreeders' society were even better: the incidence of cats positive for FeLV decreased from 11% in 1974 to less than 2% within 4 years. None of the cats tested in this society has been found to be positive for FeLV since 1984. Besides removal programmes, other methods of control, such as pre-exposure treatment, were developed to prevent the spread of FeLV. We attempted to protect kittens against oronasal infection with FeLV by treatment with virus-neutralizing (VN) monoclonal antibodies (MoAbs) directed against an epitope on the viral glycoprotein gp70. However, no protection was achieved. It is unlikely that the amount of VN antibodies, the mode and route of their application or the infectious dose of FeLV used can account for this failure. Other possible explanations for the lack of protective effect are that (i) the restricted epitope specificity of the MoAb preparation used may have led to selection of neutralization-resistant virus mutants, or (ii) other mechanisms than virus neutralization (complement-mediated lysis, antibody-dependent cell cytotoxicity), that may be involved in protection, function less efficiently with MoAb. However, in the light of our finding that an early anti-idiotypic response is observed in all cats following administration of the MoAb preparation, the rapid clearance of anti-FeLV MoAb from the circulation is a more likely explanation. Efforts were further made to develop a vaccine for controlling FeLV infection. The immunostimulating complex vaccine (FeLV-ISCOM vaccine), a subunit vaccine in which FeLV gp70 is presented in a particular manner, looks promising. The protective effect of FeLV-ISCOM vaccine was studied by vaccinating six 8-week-old SPF cats with ISCOM, followed by oronasal challenge with FeLV.(ABSTRACT TRUNCATED AT 400 WORDS)
Weijer
K
K
The Netherlands Cancer Institute, Division of Immunology, Amsterdam.
Uytdehaag
F G
FG
Osterhaus
A D
AD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002371:Cat Diseases / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D002415:Cats; D007116:Immunization, Passive; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007938:Leukemia / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary*; D005256:Leukemia Virus, Feline / Q000276:immunology* / Q000302:isolation & purification; D015682:Retroviridae Proteins, Oncogenic; D014611:Vaccination / Q000662:veterinary; D014759:Viral Envelope Proteins; D014765:Viral Vaccines
D000911:Antibodies, Monoclonal; D007130:Immunoglobulin Idiotypes; D015682:Retroviridae Proteins, Oncogenic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine